James Snodgrass has over two decades of experience in qualitative and policy research engagements for clients such as Merck & Co, Abbott, the Bill & Melinda Gates Foundation, the Hewlett Foundation, and the John Hopkins School Bloomberg School of Public Health.
James offers exceptional expertise in health policy research and development, global product positioning, communications planning, stakeholder and donor relationships, demand forecasting, and advocacy. He has extensive knowledge and understanding of the healthcare systems in Europe and many sub-Saharan African countries. He is adept at using diverse data to influence the highest levels of health policy decision-making. Some past projects include
- looking at potential demand for HIV vaccines for Merck & Co in 28 rich and poor countries
- a major stakeholder mapping project for ViiV Healthcare, focusing on global influencers in HIV/AIDS
- a collaboration with RAND Europe doing market access research in hepatitis C
James’ main areas of specialisation are vaccines, treatments and innovative funding, and his expertise has been used by the Bill & Melinda Gates Foundation, the AERAS TB Vaccine Foundation, the Hewlett Foundation, and the John Hopkins School Bloomberg School of Public Health, amongst others. He has worked for leading global health organisations, including the (UK) Department for International Development (DFID), Rockefeller Foundation and the International HIV/AIDS Alliance, and an extensive portfolio of pharmaceutical clients, including Merck & Co, Abbott, Roche, Schering Plough, and Ferring, with work for the latter company focused on treatment for preterm birth.
- strategy development
- project management
- analysing, writing and presenting policy research data and evaluation frameworks related to public health issues, primarily related to medicines and vaccines.
- Associate, Baird’s CMC
- AERAS TB Vaccine Foundation
- the Bill & Melinda Gates Foundation
- the Hewlett Foundation
- the John Hopkins Bloomberg School of Public Health
- the International AIDS Vaccine Initiative
- Merck & Co., Inc.